Maintain Neutral: Topchoice Medical's operational resilience is decent, but the FY26 growth target still needs volume validation

Overview

This report is J.P. Morgan's earnings review and valuation update on Topchoice Medical Investment Co.- A. The report believes the company delivered relatively solid revenue, profit, and cash flow performance in FY25 and 1Q26 against a weak consumption backdrop, and the growth in operating cash flow indicates that earnings quality remains supported. However, the recovery pace of the dental implant and orthodontics businesses was slower than expected, and it remains to be seen whether low-price products, lower-tier market expansion, and grid marketing can drive delivery of the company's ambitious FY26 targets.

Core views

The core view is that 'operational resilience remains, but clearer evidence of business recovery is needed before turning more constructive.' The company is maintaining its FY26 sales growth target of around 30%, mainly relying on low-price products, reforms to doctor incentive mechanisms, the private label Yinxiu, and grid marketing to expand penetration in lower-tier markets. J.P. Morgan acknowledges the strategic direction, but considers the FY26 targets of 200k dental implants and 50k orthodontic cases highly aggressive, and therefore sets FY26 sales growth at 13% in its model and cuts FY26E/27E EPS.

Analysis framework

The report combines earnings breakdown, core business volume-price analysis, management strategy assessment, and DCF valuation. On operations, it focuses on tracking revenue, net profit, operating cash flow, gross margin, net margin, dental implant volume and ASP, orthodontic case volume, as well as penetration in Zhejiang Province and the execution of grid marketing; on valuation, it uses DCF and cross-checks against FY26E P/E.

Methodology notes

• Valuation methodsDCF

  Dec-26 target price of Rmb42 is based on DCF valuation

  The DCF assumes a risk-free rate of 3.8%, market risk premium of 6.2%, beta of 1.4, WACC of 11.5%, terminal growth rate of 2.5%, and forecasts free cash flow through 2033.

• Earnings ForecastEPS forecast revision

  FY26E/27E EPS cut

  J.P. Morgan lowered its FY26E/27E EPS forecasts by 12%/14% respectively to reflect the slower-than-expected recovery in dental implants and orthodontics, while slightly raising future net margin assumptions to reflect improved refined management of the existing store base.

• Operational AnalysisVolume-price mix analysis

  Volume-price breakdown of dental implants and orthodontics

  The report breaks down growth drivers into dental implant volume, ASP, VBP mix, promotion of low-price products, orthodontic case volume, and the cost advantage of the Yinxiu brand.

• Strategy AssessmentPenetration and grid marketing assessment

  Validation of lower-tier penetration and grid marketing execution

  The report believes lower-tier markets, the membership system, and community grid staff can expand the customer base, but recruitment of grid staff, sales ramp-up per staff member, and the impact on ASP and gross margin need to be monitored.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 600763.SS / Topchoice Medical Investment Co.- A

  Covered company; China A-share dental chain service company

  Strengths

  The company is one of China's leading dental chains, with 90+ medical institutions and about 3,100 dental chairs as of 3Q25; it has a solid foundation in Zhejiang Province, improving operating cash flow, and low-price products, lower-tier markets, and the membership system may bring near-term growth.

  Weaknesses

  Dental services face weak consumption and profit pressure, dental implant ASP is under pressure, the FY26 target is significantly aggressive, and evidence of business recovery is still insufficient.

  Comparison

  Management's FY26 sales growth target of around 30% is significantly above J.P. Morgan's modeled 13% sales growth forecast; the FY26 target of 200k dental implants is about 3x FY25's 65k, and the target of 50k orthodontic cases is about 2x FY25's roughly 24k.

  Risks

  Recruitment of grid staff and sales ramp-up per staff member are slower than expected, the low-price strategy fails to drive volume, demand recovery for dental implants and orthodontics in lower-tier markets is insufficient, and profits from premium products are eroded.

Key data

• Current share priceRmb41.07As of April 20, 2026.
• Target priceRmb42.00Dec-26 target price, unchanged.
• RatingNeutralMaintain Neutral rating.
• FY25 revenue growth1.4% YoYFY25 revenue was Rmb2,913mn.
• 1Q26 revenue growth1.4% YoYStill maintained slight growth in a weak consumption environment.
• FY25 operating cash flow growth6.3% YoYImproved operating cash flow is one of the main positives.
• 1Q26 operating cash flow growth9.1% YoYIndicates relatively solid earnings quality.
• FY25 dental implant volumeabout 65k unitsDown 1.4% YoY, with revenue of Rmb519mn, down 2.1% YoY.
• 1Q26 dental implant volume15.6k unitsUp 2.8% YoY, with ASP of about Rmb7,680.
• FY25 orthodontic case volumeabout 24k casesUp 10.8% YoY, with revenue of Rmb510mn, up 7.6% YoY.
• Management FY26 sales targetabout 30% growthJ.P. Morgan believes the target is quite ambitious and requires execution validation.
• J.P. Morgan FY26 sales growth forecast13%Below management's target and more conservative.
• FY26E/27E EPS revision-12% / -14%Reflects slower-than-expected recovery in dental implants and orthodontics.
• FY26E EPSRmb1.27Previous value was Rmb1.44.
• FY27E EPSRmb1.50Previous value was Rmb1.74.
• WACC11.5%Core DCF assumption.
• Terminal growth rate2.5%Core DCF assumption.

Impact & implications

The implication for the investment view is that the current share price offers limited upside versus the target price, making it more appropriate in the short term to wait for strategy execution data rather than upgrade the view in advance. If low-price products and grid marketing significantly drive volume growth in dental implants and orthodontics without materially eroding gross margin, valuation and earnings expectations could be revised upward; if volume growth falls short or profitability of premium products is damaged, management's FY26 target and market confidence may come under pressure.

Risks

• Upside risks include stabilization in dental implant pricing, accelerating penetration, stronger-than-expected recovery in orthodontic demand, breakthroughs in hospital expansion outside Zhejiang Province, improved doctor retention from better incentives, and improved operating efficiency driven by digitalization.
• Downside risks include slower-than-expected recruitment of grid staff, ineffective low-price strategy, inability of dental implant and orthodontic volumes to ramp in lower-tier cities, and greater-than-expected profit damage to premium product lines.
• Management's FY26 sales growth target is high, and without validation from actual volume and margin data, the market may continue to apply a valuation discount.
• The weak consumption environment may continue to suppress ticket size and consumer conversion in dental services.

What to watch

• Whether dental implant volume can continue accelerating from 15.6k units in 1Q26 and approach the pace required for the FY26 target of 200k units.
• Whether orthodontic case volume can ramp from about 24k cases in FY25 toward the FY26 target of 50k cases.
• The impact of the Rmb1,999 and Rmb2,999 low-price product tiers on ASP, gross margin, and premium product lines.
• The number of grid marketing agents recruited, sales output per agent, customer acquisition quality, and brand consistency.
• The return on investment and market share gains of the network of 65-70 hospitals within Zhejiang Province.
• Whether operating cash flow and net margin can remain stable under the low-price strategy.